Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

Commitments and Contingencies (Details Narrative)		1 Months Ended			3 Months Ended	9 Months Ended
Commitments and Contingencies (Details Narrative)	May 01, 2020 d / Tradingdays $ / shares shares	Nov. 30, 2019 USD ($)	Nov. 30, 2017 USD ($)	Nov. 30, 2016 USD ($) ft²	Sep. 30, 2020 $ / shares shares	Sep. 30, 2020 USD ($) $ / shares shares	Apr. 15, 2020 shares	Dec. 31, 2019
Monthly lease payments						$ 169,264
Alachua Facility [Member]
Period of lease								5 years
Tampa Facility [Member]
Period of lease		36 years		36 months
Area of office space leased \| ft²				2,207
Lease expiry date				Feb. 29, 2020
Minimum [Member] \| Amended Lease Agreement [Member]
Monthly lease payments						12,870
Minimum [Member] \| Tampa Facility [Member]
Monthly lease payments		$ 4,524		$ 4,138
Maximum [Member] \| Tampa Facility [Member]
Monthly lease payments		$ 4,800		$ 4,392
Warrants [Member] \| Noachis Terra Inc. [Member]
Payment for contingent consideration						$ 1,220,781
2018 Warrants [Member]
Warrants exercise price per share \| $ / shares					$ 1.00	$ 1.00
Number of shares issued for warrants \| shares					760,000
Warrants to purchase \| shares					4,294,500	4,294,500
2019 Warrants [Member]
Warrants exercise price per share \| $ / shares					$ 0.90	$ 0.90
Number of shares issued for warrants \| shares					4,882,114
Warrants to purchase \| shares					9,583,334	9,583,334
Short Term Warrants [Member]
Warrants to purchase \| shares							38,000
Trading days \| d / Tradingdays	21
Warrants maturity date							May 14, 2020
Stock Purchase Agreement [Member] \| Warrants [Member] \| Noachis Terra Inc. [Member]
Warrants exercise price per share \| $ / shares	$ 1.25
Contingent consideration description	(i) twenty percent (20%) of the cash proceeds received by the Company upon exercise of the Company's warrants carrying an exercise price of $0.75 and $0.90 and (ii) forty-five percent (45%) of the cash proceeds received by the Company upon exercise of the Company's warrants carrying an exercise price of $1.00, in each case, for so long as the warrants remain outstanding.
Percentage of warrant exercise	20.00%
Warrants exercise term description	The Company’s previously issued warrants carrying an exercise price of $0.75 have expired by their terms. As a result, no additional consideration will be due to the former sole shareholder of NTI relating to these warrants.
Warrants to purchase \| shares	9,200,000
Stock Purchase Agreement [Member] \| Warrant One [Member] \| Noachis Terra Inc. [Member]
Percentage of warrant exercise	45.00%
Stock Purchase Agreement [Member] \| Mr. Joseph Hernandez [Member] \| Warrants [Member] \| Minimum [Member]
Warrants exercise price per share \| $ / shares	$ 0.75
Stock Purchase Agreement [Member] \| Mr. Joseph Hernandez [Member] \| Warrants [Member] \| Minimum [Member] \| Noachis Terra Inc. [Member]
Warrants exercise price per share \| $ / shares	0.75
Stock Purchase Agreement [Member] \| Mr. Joseph Hernandez [Member] \| Warrants [Member] \| Maximum [Member]
Warrants exercise price per share \| $ / shares	0.90
Stock Purchase Agreement [Member] \| Mr. Joseph Hernandez [Member] \| Warrants [Member] \| Maximum [Member] \| Noachis Terra Inc. [Member]
Warrants exercise price per share \| $ / shares	0.90
Stock Purchase Agreement [Member] \| Mr. Joseph Hernandez [Member] \| Warrant One [Member]
Warrants exercise price per share \| $ / shares	$ 1.00
Percentage of warrant exercise	45.00%
License Agreement [Member]
Royalty expenses						$ 30,000
Reimbursement expenses						11,739
Lantibiotic Exclusive Channel Collaboration [Member]
Royalty rate percentage description			The Lantibiotic ECC was amended to: (i) consolidate the development milestone payments into one payment of $25,000,000, being due six months after receiving FDA approval of a New Drug Application, (ii) reduce the sublicense revenue percentage we would have had to pay from 50% to 25% of sublicensing revenue, (iii) reduce the royalty rate from 25% of Product Profit to 10% of Net Sales, (iv) revise the form of milestone payments from being share based or cash at the Company's election to only cash, and (v) commit that Diligent Efforts (as defined in the Lantibiotic ECC) in pursuing the Lantibiotic Program would be deemed satisfied in 2018 provided that at least $1,200,000 was budgeted for the advancement of the Lantibiotic Program.
Royalty payment of sublicenses percentage			25.00%
Amount required to expended for advancement of lantibiotic program			$ 1,200,000
Lantibiotic Exclusive Channel Collaboration [Member] \| Net Sales [Member] \| Amendment [Member]
Royalty payment percentage			10.00%
Lantibiotic Exclusive Channel Collaboration [Member] \| Cost Of Revenue [Member]
Royalty payment percentage			25.00%
Lantibiotic Exclusive Channel Collaboration [Member] \| Product Profit [Member]
Reduction in royalty rate percentage			25.00%
Lantibiotic Exclusive Channel Collaboration [Member] \| Net Sales [Member]
Reduction in royalty rate percentage			10.00%
Lantibiotic Exclusive Channel Collaboration [Member] \| New Drug Application [Member]
Milestone payment under licensing agreement			$ 25,000,000
Milestone measurement period			6 months
Lantibiotic Exclusive Channel Collaboration [Member] \| Regulatory Approval Milestone Event [Member]
Milestone payment under licensing agreement			$ 25,000,000
Milestone measurement period			6 months
Lantibiotic Exclusive Channel Collaboration [Member] \| New Indication Milestone Event [Member]
Milestone payment under licensing agreement			$ 5,000,000
Milestone measurement period			6 months
Lantibiotic Exclusive Channel Collaboration [Member] \| New Product Milestone Event [Member]
Milestone payment under licensing agreement			$ 5,000,000
Milestone measurement period			6 months
Amended Lease Agreement [Member] \| Maximum [Member]
Monthly lease payments						$ 13,338